Levocetirizine Dihydrochloride Tablet
FDA Label NDC 42571-312

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Micro Labs Limited for the product Levocetirizine Dihydrochloride (NDC 42571-312). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding active ingredient (in each tablet), purpose, uses, do not use, ask a doctor before use if you have, when using this product, stop use and ask a doctor if, if pregnant or breast-feeding:, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Active Ingredient (In Each Tablet)

Levocetirizine dihydrochloride USP 5 mg

Purpose

Antihistamine

Uses

  temporarily relieves these symptoms due to hay fever or other respiratory allergies:

  • runny nose
  • sneezing
  • itchy, watery eyes
  • itching of the nose or throat

Do Not Use

  • if you have kidney disease
  • if you have ever had an allergic reaction to this product or any of its ingredients or to an antihistamine containing cetirizine
    • if you have kidney disease
    • if you have ever had an allergic reaction to this product or any of its ingredients or to an antihistamine containing cetirizine

Ask A Doctor Before Use If You Have

  • ever had trouble urinating or emptying your bladder

When Using This Product

  •  drowsiness may occur
  • avoid alcoholic drinks
  • alcohol, sedatives, and tranquilizers may increase drowsiness
  • be careful when driving a motor vehicle or operating machinery

Stop Use And Ask A Doctor If

  • you have trouble urinating or emptying your bladder
  • an allergic reaction to this product occurs. Seek medical help right away.

If Pregnant Or Breast-Feeding:

  • if breast-feeding: not recommended
  • if pregnant: ask a health professional before use

Keep Out Of Reach Of Children.

In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).

Directions


adults 65 years of age and older
  • ask a doctor
adults and children 12-64 years of age
 
  • take 1 tablet (5 mg) once daily in the evening
  • do not take more than1 tablet (5 mg) in 24 hours
  • ½ tablet (2.5 mg) once daily in the evening may be appropriate for less severe symptoms
children 6-11 years of age
  • take ½ tablet (2.5 mg) once daily in the evening
  • do not take more than ½ tablet (2.5 mg) in 24 hours
children under 6 years of age
  • do not use
consumers with kidney disease
  • do not use


Storage

  • store between 20° and 25°C (68° and 77°F)
  • safety sealed: do not use if carton was opened or torn

Inactive Ingredients

hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400 and titanium dioxide

Questions Or Comments?

call1-855-839-8195



Principal Display Panel


MICRO LABS LIMITED
Container


NDC- 42571-312-90
Levocetirizine dihydrochloride Tablets USP
5mg
Antihistamine

90 Tablets    MICRO LABS

Micro Labs Container Label (Levo Microcontainerlabel)

Micro Labs Container Label (Levo Microcontainerlabel)


Container-Carton



NDC- 42571-312-90
Levocetirizine dihydrochloride Tablets USP
5mg
Antihistamine

90 Tablets    MICRO LABS

Micro Labs Carton Label (Levo Microcartonlabel)

Micro Labs Carton Label (Levo Microcartonlabel)



INVATECH PHARMA SOLUTIONS LLC
Container




NDC- 42571-312-90
Levocetirizine dihydrochloride Tablets USP
5mg
Antihistamine

90 Tablets    MICRO LABS

Invatech Pharma Container Label (Levo Invatechcontainerlabel)

Invatech Pharma Container Label (Levo Invatechcontainerlabel)


Container-Carton



NDC- 42571-312-90
Levocetirizine dihydrochloride Tablets USP
5mg
Antihistamine

90 Tablets    MICRO LABS

Invatech Pharma Carton Label (Levo Invatechcartonlbl)

Invatech Pharma Carton Label (Levo Invatechcartonlbl)

* Please review the disclaimer below.